Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer

McCorkle, JR; Gorski, JW; Liu, JP; Riggs, MB; McDowell, AB; Lin, N; Wang, C; Ueland, FR; Kolesar, JM

Kolesar, JM (corresponding author), Univ Kentucky, Coll Med, Markey Canc Ctr, Lexington, KY 40506 USA.; Kolesar, JM (corresponding author), Univ Kentucky, Coll Pharm, Lexington, KY 40506 USA.

PLOS ONE, 2021; 16 (8):

Abstract

Conventional frontline treatment for ovarian cancer consists of successive chemotherapy cycles of paclitaxel and platinum. Despite the initial favorab......

Full Text Link